The Quantellect read.As of Nov 19, 2026, 14 active firms cover Opus Genetics, Inc: 14 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $7.00 to $20.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $13.00 sits 232% above the current $3.92. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 13 to 14 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.15 next quarter toward $-0.76 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 active firms
Buy
Strong Buy00%
Buy14100%
Neutral00%
Sell00%
Strong Sell00%
Based on 14 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$13.00
+231.6% upside
Average target across 13 active firms as of Nov 19, 2026 vs $3.92 current
Highest Target$20.00
Average Target$13.00
Lowest Target$7.00
Detailed analyst forecasts for IRD
Showing 1–13 of 13 named analysts shown · 14 active firms in the rating projection
As of Nov 19, 2026, 14 of 14 active firms rate IRD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IRD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.15
Range $-0.19 – $-0.13 · 3 analysts · -80% YoY
Next period, 3 analysts expect Opus Genetics, Inc. to earn $-0.15 a share (range $-0.19 – $-0.13), versus $-0.75 a year earlier. Full-year consensus is $-1.29, growing to $-0.76 the year after.
REVENUE · NEXT QUARTER
$1.7M
Range $0 – $2.9M · 3 analysts · -22% YoY
Revenue is expected to reach $1.7M (range $0 – $2.9M), -22.1% year-over-year. Full-year consensus is $13.3M, rising to $12.1M next year.
Top analysts covering Opus Genetics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IRD.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$9.00+129.6% to target
Overall win rate
49%
+ Follow
#2
Daniil Gataulin
Chardan Capital · Rank #51
Buy
$11.00+180.6% to target
Overall win rate
52%
+ Follow
#3
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$11.00+180.6% to target
Overall win rate
43%
+ Follow
#4
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$8.00+104.1% to target
Overall win rate
49%
+ Follow
#5
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$16.00+308.2% to target
Overall win rate
39%
+ Follow
IRD stock forecast FAQ
What is IRD's average 12-month price target?+
The 13 active firms with a live target average $13.00 for Opus Genetics, Inc. over the next 12 months, ranging from a $20.00 high to a $7.00 low, as of Nov 19, 2026.
Is IRD stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 14 active firms as of Nov 19, 2026, 14 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IRD?+
The Street-high target is $20.00 (Oppenheimer), and the Street-low is $7.00 (Piper Sandler). The average of all 13 active-firm targets is $13.00.
How many active Wall Street firms cover IRD?+
14 active firms have a recognized rating on Opus Genetics, Inc. as of Nov 19, 2026, and 13 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IRD?+
Among analysts who currently cover IRD, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $9.00 target.
What is Opus Genetics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.15 per share (range $-0.19 – $-0.13) across 3 analysts. Full-year EPS is projected at $-1.29, rising to $-0.76 the following year.
How much revenue is Opus Genetics, Inc. expected to report next quarter?+
Consensus revenue is $1.7M (range $0 – $2.9M). Full-year revenue is projected at $13.3M, growing to $12.1M next year.
Have analysts been upgrading or downgrading IRD lately?+
As of Nov 19, 2026, 14 of 14 active firms rate IRD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IRD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.